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Fibroblast-conditioned mediaIt is well established that glucocorticoids elevate the production of ﬁbroblast-pneumocyte factor
(FPF), which induces type II cells to synthesize surfactant phospholipids. FPF, however, has not been
identiﬁed and it is not clear whether it is a single factor or a complex mixture of factors. In this study
it has been shown that, when lung ﬁbroblasts are exposed to dexamethasone, the concentration of
neuregulin-1b (NRG1b) in conditioned medium is elevated 2-fold (P < 0.05), even though NRG1b gene
expression is unaffected. This, together with the ﬁnding that exposure of type II cells to NRG1b
directly stimulates by 3-fold the rate of phospholipid synthesis (P < 0.05), suggests that NRG1b is a
component of FPF that promotes lung development.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The fetal lung undergoes extensive physiological and biochem-
ical maturation prior to birth in preparation for its postnatal func-
tion as an organ for gas exchange. Pulmonary surfactant, a
substance that reduces surface tension and prevents alveolar col-
lapse, is produced by type II pneumocytes in the developing lung
[1,2]. Any reduction in the ability of type II cells to produce surfac-
tant leads to neonatal respiratory distress syndrome (NRDS) [1].
Synthesis of the major phospholipid component of surfactant,
phosphatidylcholine, was shown to be stimulated by glucocorti-
coids [3] even though they have no effect when directly applied
to type II cells. However, when lung ﬁbroblasts were cultured in
the presence of glucocorticoids, the resultant ﬁbroblast-condi-
tioned media (FCM) is known to stimulate surfactant production
in cultured type II cells [4]. This indirect effect of glucocorticoids
upon surfactant phospholipid synthesis was attributed to a ﬁbro-
blast-derived peptide, termed ﬁbroblast-pneumocyte factor (FPF)
[5]. It was subsequently reported that puriﬁed FPF was able to di-
rectly stimulate the synthesis of surfactant-associated phospholip-
ids [6]. Even though several peptides have been shown to have
properties similar to FPF [7–9], the chemical nature of FPF is still
not certain.Torday et al. [7] have shown that leptin, a 16 kDa peptide ex-
pressed by fetal lung ﬁbroblasts, stimulates de novo synthesis of
surfactant phospholipids in type II cells. Coupled with the observa-
tion that dexamethasone, which is known to stimulate production
of FPF, also stimulated expression of leptin mRNA, they concluded
that leptin might be FPF [7]. However, neuregulin-1b (NRG1b) has
also been shown to play a major role in the development and mat-
uration of the fetal lung. Dammann et al. [8] provided evidence
that the stimulation of surfactant synthesis in type II cells by media
previously conditioned by ﬁbroblasts in the presence of dexameth-
asone can be mimicked by NRG1b and inhibited by antibodies
raised against this peptide.
Neuregulins are part of the epidermal growth factor (EGF) fam-
ily [10], and interact with several members of the ErbB family of
receptors [11]. NRG1b is known to have a role in the early stages
of lung development [12], and ErbB receptors are distributed
throughout the developing lung [12,13]. Dammann et al. showed
that dexamethasone, a steroid used to stimulate production of
FPF by ﬁbroblasts, also regulated levels of ErbB receptors in the fe-
tal lung [14]. Zscheppang et al. used small interfering RNA to show
that ErbB4 regulates surfactant phospholipid synthesis in the fetal
rat type II cells [15].
Surfactant production is also induced by keratinocyte growth
factor (KGF) [16–18], otherwise known as ﬁbroblast growth factor
7. This peptide is a product of lung mesenchymal cells and stimu-
lates both the synthesis of the major component of surfactant,
disaturated phosphatidylcholine, as well as the expression of the
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although KGF has many of the properties of FPF, its size (28 kDa)
[19] is much larger than the 5–15 kDa ascribed to FPF [20]. Thus,
in this study the focus was on the speciﬁc effects of leptin and neu-
regulin-1b on surfactant phospholipid synthesis and secretion in
cultured fetal type II pneumocytes.
From the above it is clear that NRG1b performs an important
role in this system, although the exact details of the mechanism
have not been elucidated. In this study we have examined the ef-
fect of NRG1b on surfactant phospholipid synthesis over a range
of concentrations and exposure times, and have also compared
the effects of NRG1b and leptin on this synthesis. In addition, the
effect of dexamethasone on NRG1b production by ﬁbroblast cells,
including mRNA expression and direct quantiﬁcation using liquid
chromatography–mass spectrometry (LC–MS), was examined.
2. Materials and methods
2.1. Animals
Nineteen-day pregnant rats of the Wistar strain of Rattus nor-
vegicus (22-day gestation period) were supplied by the Animal Re-
source Centre (Murdoch, Australia). The presence of sperm in a
vaginal smear after overnight mating indicated conception had oc-
curred and was designated day zero. Experiments complied with
National Health and Medical Research Council guidelines, and
were approved by the university’s Animal Ethics Committee.
2.2. Materials
Eagle’s minimal essential medium (MEM) and newborn bovine
serum (NBCS) were obtained from Thermo Fisher Scientiﬁc (Wal-
tham, USA). Radiolabelled compounds were supplied by GE Health-
care (Little Chalfont, UK). HPLC grade acetonitrile was obtained
from Burdick and Jackson (Muskegon, USA) andwater was obtained
from a Milli-Q system (Millipore Corp., Billerica, USA). Lyophilized
recombinant human neuregulin-1b (heregulin-1b, 7.5 kDa) (Pepro-
Tech, Rocky Hill, USA) was reconstituted in Milli-Q water. The SV
total RNA isolation and OneStep RT-PCR kits used for RT-PCR reac-
tions were purchased from Promega Corporation (Madison, WI,
USA) and Qiagen Sciences (Germantown, MD, USA), respectively.
All other reagents were supplied by Sigma Aldrich (St. Louis, USA).
2.3. Preparation of media
Eagle’s minimal essential medium was reconstituted according
to the manufacturer’s speciﬁcations, supplemented with 0.2%
NaHCO3 and adjusted to pH 7.4. To this was added L-glutamine,
penicillin G and streptomycin sulfate to ﬁnal concentrations of
2.6 mM, 100 IU/mL and 135 lM, respectively. The medium was
then sterilized by ﬁltration through a 0.22 lm ﬁlter and amphoter-
icin was added to a ﬁnal concentration of 3.2–3.6 lg/mL. The med-
ium was then supplemented to include 10% charcoal-treated NBCS.
2.4. Isolation of ﬁbroblasts and type II pneumocytes
Pregnant rats (19 days gestation) were asphyxiated with CO2
and fetuses delivered by Caesarean section. The fetal lungs were
removed, minced and incubated with collagenase (0.05 IU/mL)
for 20 min in a 37 C shaking water bath, as previously described
[21,22]. After ﬁltration through two layers of sterile French voile,
the cells were centrifuged at 20g for 2 min and the pellet resus-
pended in serum-free medium. This suspension was plated
(6 lungs per plate) onto 6 cm diameter culture plates (Corning LifeSciences, Lowell, USA) and incubated for 30 min at 37 C in a
humidiﬁed CO2 incubator to allow adhesion of ﬁbroblasts. Non-
adhering cells were removed by gentle swirling and the medium
replaced with serum-containing media. The non-adhering cells
were used to isolate type II pneumocytes, according to the method
of Dobbs et al. [23]. The type II cell medium was changed after 24
and 72 h. When the cells had been cultured for 3 days the cultures
were nearly conﬂuent and consisted predominantly of differenti-
ated type II cells, each containing numerous lamellar bodies and
being capable of both synthesis [21] and secretion [22,24] of sur-
factant phosphatidylcholine.
2.5. Preparation of ﬁbroblast-conditioned medium
Conﬂuent ﬁbroblast cultures were considered free of contami-
nation from type II cells as judged by microscopy. Media was re-
moved from the plates and replaced with serum-free medium
supplemented with either dexamethasone in propylene glycol or
vehicle (control). Plates were returned to the incubator for a fur-
ther 24 h, after which FCM was collected and stored at 80 C.
Prior to assay, each FCM was thawed and heat-treated at 65 C
for 60 min to remove known inhibitory factors [5]. After cooling
to room temperature, they were ﬁltered through 0.22 lm ﬁlters
and diluted 1:4 with serum-free medium.
2.6. Assay of synthesis of surfactant phospholipids
The medium from conﬂuent type II pneumocyte cultures was
removed and replaced with 3.0 mL of either diluted FCM supple-
mented with the corresponding additives or serum-free media
supplemented with the indicated concentrations of heregulin-1b
or leptin. After 21 h of culture, serum-free medium containing
[methyl-3H]-choline chloride (ﬁnal concentration 1.0 lCi/mL)
was added and the plates further incubated for the indicated times.
After this ﬁnal incubation, incorporation of [3H]-choline into cellu-
lar surfactant phospholipid (expressed as dpm/lg DNA) was deter-
mined as described by Sen and Cake [21]. The radiolabelled
material produced using this method was previously validated
using TLC and shown to consist predominantly (>85%) of phospha-
tidylcholine (PC), of which disaturated PC was the major compo-
nent [22].
2.7. RT-PCR quantiﬁcation
The RT-PCR primers for the GAPDH and NRG1b mRNA assays
were designed to include a splice junction between the forward
and reverse primers thereby providing the means of distinguish-
ing between the products of mRNA and genomic DNA based on
the size of the products. Each of the primers were checked for
melting temperature (TM) and cross reactivity with other se-
quences using Primer3 and BLAST software, respectively. Agarose
electrophoresis of the RT-PCR products demonstrated that nei-
ther primer dimer formation nor interference with GAPDH prim-
ers were evident. The forward and reverse primer sequences
chosen for the GAPDH and NRG1b RT-PCR assays are shown
below:Primer Size
(bp)Forward primer
sequenceReverse primer
sequenceGAPDH 207 50-agacagccgcat
cttcttgt-3050-cttgccgtggg
tagagtcat-30NRG1b 196 50-acgactgggac
cagccatc-3050-tctggtagagtt
cctccgctttg-30
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atures approximately 10 C higher than either of the forward and
reverse primers, were designed with an Iowa Black quencher at
the 30 end and FAM (green) or Cy5 (red) covalently attached at
the 50 end, respectively. The sequence of these probes is shown
below:Fi
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30NRG1b Cy5 50(Cy5)-tggcaacgatcaccagtaaactcatttgg-
(IAbRQSp) 30Total cellular RNA was extracted using a SV Total RNA Isolation Sys-
tem (Promega Corporation, Madison, WI, USA). All pipette tips and
microcentrifuge tubes used were certiﬁed nuclease-free. Following
extraction, RNA extracts were stored at 70 C until quantiﬁcation.
RNA quantiﬁcation of each extract was made using an Agilent 2100
Bioanalyzer with an Agilent RNA 6000 Pico kit (Agilent Technolo-
gies Inc., Santa Clara, CA, USA). The extracts were diluted such that
an aliquot containing 5 ng of mRNA was added to each RT-PCR.
To measure relative gene expression, QIAGEN OneStep RT-PCR
was undertaken using a QIAGEN Rotor-Gene Q6000 (QIAGEN, Hil-
den, Germany). For each RNA extract, a PCR reaction was set-up in
a UV-sterilised, RNase-free PCR tube (Axygen – Fisher Biotec, Perth,
Western Australia), containing forward and reverse primers as well
as the TaqMan probes for GAPDH and NRG1b. It was established
that an annealing temperature of 57 C provided the best speciﬁc-
ity and the highest yield of product. Thus, the reaction mixtures
were incubated at 50 C for 30 min followed by denaturation at
95 C for 15 min. This was followed by 40 cycles using the follow-
ing parameters; 94 C for 30 s; 57 C for 30 s and 72 C for 60 s. The
reactions were then held at 72 C for 10 min. The RT-PCR products
were then analysed for the expression of NRG1b relative to GAPDH
using the method of Pfafﬂ [25].
2.8. Liquid chromatography–mass spectrometry (LC–MS)
Mass spectrometry was undertaken using an Agilent Classic ser-
ies ion trap mass spectrometer. The MS was operated in positive
ionization mode using electrospray ionization. Nebulizer pressure0
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325 C. Standards and samples were infused directly into the MS
at 5 lL/min using a KD Scientiﬁc 100 syringe pump (KD Scientiﬁc,
Holliston, USA). Two identiﬁer ions were selected: m/z 1068.5
([M+7H]7+), and 1246.7 ([M+6H]6+). MS/MS was performed on m/
z 1068.5, and this generated fragment ions, of which m/z 958.3
(a263+), 1028.7 (y26+) and 1047.3 were selected.
To allow quantiﬁcation, an Agilent 1100 capillary HPLC (Agilent
Technologies) was coupled to the ion trap MS. The analytical col-
umn used was an Agilent Zorbax 300SB-C18 capillary column with
dimensions of 100  0.3 mm with 3.5 lm particle size. Mobile
phase solvents consisted of (A) water + 0.1% formic acid and (B)
acetonitrile + 0.1% formic acid. Flow rate was set at 5 lL/min with
a gradient as follows (A:B): 0 min–90:10, 10 min-90:10, 25 min–
0:100, 35 min–0:100. Standard NRG1b eluted at a retention time
of 12.5 min, and a standard curve for NRG1b was prepared in trip-
licate over the range of 0.01–1.33 nM. This curve showed a very
strong correlation (R = 0.998).
2.9. Data analysis
Statistical analyses were performed using SPSS Statistics for
Windows 21.0. Repeated measures ANOVA [26] was used to ana-
lyze the time-course experiment and for ascertaining differences
between 3 or more experimental conditions. If signiﬁcance was
determined in the later case, the ANOVA was followed by Dunnett
pairwise comparisons of the various groups. LC-MS analysis was
undertaken using Agilent ChemStation for LC 3D (Rev. B.09.03)
and Bruker-Daltonik MSD Trap Control software (v. 5.1) (Bruker-
Daltonik, Bremen, Germany).
3. Results and discussion
3.1. Effect of ﬁbroblast-conditioned medium on surfactant
phospholipid synthesis
Six pairs of control and dexamethasone-treated FCM were as-
sayed for their effect on surfactant phospholipid synthesis in cul-
tured type II pneumocytes. FCM generated in the presence of
100 nM dexamethasone enhanced by 24% the rate of surfactant
phospholipid synthesis by type II cells when compared to that
measured in control cultures (Fig. 1A; P < 0.05). Previously, this0.0
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Fig. 2. Effect of NRG1b on surfactant phospholipid synthesis. After three days in culture, fetal rat type II pneumocytes were exposed to (A) the indicated concentrations of
NRG1b or vehicle and (B) 6.67 nM NRG1b (d) or vehicle (control, j). After 21 h exposure to the peptide, the extent of incorporation of [3H-methyl]-choline chloride into
surfactant phospholipids was determined after a further incubation of (A) 6 h or (B) 2, 4 and 6 h. The results are depicted as the mean ± S.E.M. of four separate experiments.
Any signiﬁcant differences from the controls (vehicle) are denoted with an asterisk (⁄P < 0.05).
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duced by lung ﬁbroblasts and acts on type II pneumocytes to en-
hance surfactant phospholipid synthesis [6,27]. Dammann et al.
[8] observed that 1 and 10 nM NRG1bwere able to mimic the effect
of FPF, suggesting that it may be involved in the FPF response.
In order to quantify the amount of NRG1b present, the same six
pairs of control and dexamethasone-treated FCM that were used
above were also analysed by LC–MS. The mean NRG1b concentra-
tion in the control FCMwas 2.65 ± 0.23 nM, while in the test FCM it
was 5.55 ± 0.19 nM (Fig. 1B). These ﬁndings indicate that ﬁbroblast
cells produce and secrete NRG1b in the absence of dexamethasone
stimulation, but that its concentration was more than 2-fold higher
when the ﬁbroblasts were exposed to dexamethasone (P < 0.001).
This observation may account for the ﬁnding of Dammann et al.
[8] that NRG1b antibody is able to block the enhanced rate of sur-
factant synthesis in type II cells that had been exposed to FCM.
It is important to note that the effects of dexamethasone on
expression and activation of ErbB receptors in fetal mouse type II
cells were distinct from those induced by mature (d18) FCM [14].
Thus, in order to ascertain whether the glucocorticoid-induced in-
crease in NRG1b mimics natural maturation processes, additional
experiments should be conducted to determine the NRG1b concen-
tration in media conditioned by lung ﬁbroblasts isolated from fetal
rats of different gestation ages.
3.2. Effect of NRG1b on surfactant phospholipid synthesis
When type II cells were incubated with NRG1b in the range 0–
26.67 nM for 21 h, the quantity of labelled surfactant phospholipid
synthesised after 6 h was higher in those cells exposed to the pep-
tide. Synthesis was highest when cells were exposed to 2.67 nM
NRG1b, at 3648 ± 239 dpm/lg DNA, compared to 1045 ± 137
dpm/lg DNA in control cells. Similar NRG1b dose–response curves
have been seen with other cell types [28,29]. The increased level of
surfactant phospholipid synthesis in cells exposed to either 2.67 or
6.67 nM NRG1b (3269.6 ± 616.4 dpm/lg DNA) was signiﬁcantly
different from that in the controls (more than 3-fold higher;
P < 0.05) (Fig. 2A). It is important to note that the control cells in
this experiment were incubated with MEM+ whereas those in the
experiment reported in Fig. 1A were incubated with FCM, which
contains approximately 0.66 nM NRG1b (after being diluted 1:4)together with any other components of FPF (Fig. 1B). It is thus
not surprising that the level of phospholipid synthesis is much
lower in those cells maintained in MEM+ and that the observed re-
sponse to NRG1b is greater.
The response to NRG1bwas reduced at higher concentrations of
the ligand, and it is likely that the ErbB receptor to which NRG1b
binds was down-regulated at these concentrations. Although the
mechanism by which this down-regulation might occur in type II
cells is unknown, Cao et al. [30] have shown that neuregulin in-
duces both ubiquitination and degradation of the ErbB3 receptor
in MCF-7 cells. If neuregulin-induced degradation of the ErbB
receptor also occurs in type II cells this could explain the decline
in the response at higher concentrations of NRG1b. In the current
study, the commercially available form of NRG1b (heregulin-1b)
was used whereas the form used in the study by Dammann et al.
[8] is not known. Despite this, as well as the fact that the type II
cells were derived from rats and mice, respectively, elevated
phospholipid synthesis by these cells was evident at similar NRG1b
concentrations.
The quantity of radiolabelled surfactant phospholipids synthes-
ised by type II pneumocytes in the 2, 4 and 6 h following 21 h incu-
bation with 6.67 nM NRG1b was enhanced when compared with
that which occurred in cells grown in the absence of NRG1b
(Fig. 2B). The control value increased from 795.6 ± 293.1 dpm/lg
DNA at 2 h to 1888.6 ± 195.6 dpm/lg DNA at 6 h, while NRG1b-
treated cells increased from 1219.4 ± 208.8 dpm/lg DNA at 2 h to
2469.6 ± 184.1 dpm/lg DNA at 6 h. The difference between control
cultures and NRG1b-treated cells was signiﬁcant (P < 0.05) and, as
expected, there was also evidence of an increase in the rate of
phospholipid synthesis with time (P < 0.01).
In order to understand the mechanism(s) by which NRG1b ex-
erts its effect it needs to be recognized that, in mice and rats, the
response of lung cells to this peptide is mediated via ErbB receptors
[14,15,31]. Using a small interfering RNA (siRNA), which targeted
the ErbB4 gene and silenced ErbB4 receptor activity in cultured
19-day fetal type II pneumocytes, Zscheppang et al. [15] demon-
strated that the resulting down-regulation of the ErbB4 receptor
caused a diminished rate of surfactant phospholipid synthesis.
Their conclusion that the response of these cells to NRG1b is med-
iated through ErbB4 receptor activation was supported by the
observation that exposure of both fetal and adult rat lung epithelial
Table 1
Expression of the NRG1b gene in lung ﬁbroblasts after exposure to dexamethasone.
Cultured fetal rat lung ﬁbroblasts were exposed to MEM+ containing 20 or 50 nM
dexamethasone or an equivalent volume of propylene glycol (vehicle). After the
indicated exposure time, the cells were subjected to RNA extraction and the mRNA
concentration of these extracts quantiﬁed. The level of NRG1bmRNA was determined
using multiplex qPCR and the data represent the mean ± S.E.M. of the indicated
number of independent ﬁbroblast cultures.
Exposure
time (h)
NRG1b gene expression in lung ﬁbroblasts after exposure
to dexamethasone (relative to a control value of 1.00)
20 nM Dexamethasone 50 nM Dexamethasone
4 0.93 ± 0.33 (5) 0.95 ± 0.41 (5)
8 0.89 ± 0.15 (6) 1.01 ± 0.35 (7)
24 0.73 ± 0.42 (3) 1.10 ± 0.80 (3)
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Fig. 3. Effect of leptin on surfactant phospholipid synthesis. Cultured fetal rat type
II pneumocytes were exposed to MEM+ containing 1.24, 3.09 and 6.17 nM leptin
( ) or an equivalent volume of vehicle (control, h). After a 21-h exposure, the cells
were further exposed to 1.0 lCi/mL [3H-methyl]-choline chloride for 4 h prior to
determining the amount of cellular radiolabelled surfactant phospholipids. The
results are depicted as the mean ± S.E.M. of four separate experiments. Any
signiﬁcant differences from the control (vehicle) are denoted with asterisks
(⁄P < 0.05; ⁄⁄P < 0.01).
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receptor [13,32].
3.3. NRG1b mRNA expression
RT-PCR analysis of the level of expression of the NRG1b gene in
cultured fetal lung ﬁbroblasts following exposure to dexametha-
sone showed no signiﬁcant difference with either 20 or 50 nM
dexamethasone (Table 1). The fold change in NRG1b mRNA levels,
relative to that of GAPDH, after exposure to 20 nM dexamethasone
ranged from 0.93-fold at 4 h to 0.73-fold at 24 h, while with 50 nM
dexamethasone, changes ranged from 0.95-fold at 4 h to 1.10-fold
at 24 h. Preliminary experiments conducted after 2 and 6 h expo-
sure to the steroid also showed no signiﬁcant elevation of NRG1b
gene expression. The absence of a signiﬁcant increase in NRG1b
gene expression following exposure to dexamethasone suggests
that the steroid does not mediate its effects via an elevated rate
of transcription of the NRG1b gene. It is well known that at least
15 different isoforms of NRG1b are produced from a single gene,
and that these forms can include transmembrane and secreted
proteins [33]. Given that neuregulins are produced as transmem-
brane precursors, which are considered to generate diffusible
ligands when subjected to cleavage [34,35], it is possible thatdexamethasone stimulates the rate of cleavage of the neuregulin
precursors. In this context it is relevant that glucocorticoids
enhance proteolytic activity in both muscle cells and thymocytes
[36,37]. Alternatively, dexamethasone may induce secretion of
pre-formed NRG1b followed by new NRG1b synthesis more than
24 h later. Thus, any transient increase in NRG1b gene expression
may occur 24 h or more after exposure to dexamethasone.
3.4. Comparison of NRG1b and leptin effects on surfactant
phospholipid synthesis
Previous studies have shown that leptin, which is expressed by
lipoﬁbroblasts during rat lung development, has many of the char-
acteristics of FPF [7,38]. Leptin, at both 1.24 (5245.8 ± 906.1 dpm/
lg DNA) and 3.09 nM (5691.0 ± 533.4 dpm/lg DNA), showed a sig-
niﬁcant increase in surfactant phospholipid synthesis compared to
the control (3183.8 ± 349.9 dpm/lg DNA) (P < 0.05 and P < 0.01,
respectively), but not at 6.17 nM (4405.4 ± 174.4 dpm/lg DNA).
Similar results were obtained by Torday et al. [7] although, in their
study, there was no decline in the response to the higher leptin
concentration. When one compares the response of these cells to
leptin (Fig. 3) with that of NRG1b (Fig. 2A) it is apparent that both
peptides stimulate surfactant phospholipid synthesis by approxi-
mately the same extent and at a similar peptide concentration
(i.e. 3 nM). On the basis of its size (16 kDa) and it having many
of the same characteristics as FPF, Torday et al. [7] suggested that
leptin may be FPF. However, as NRG1b has a molecular weight
within the range given for FPF (5–15 kDa [20]), and is produced
by lung ﬁbroblasts [8], particularly in response to glucocorticoids
as shown in this study, it too shares many of the attributes of
FPF. Given the strong evidence of a role for each of these in the pul-
monary surfactant system, it is possible that FPF consists of both
agents.
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